Kezar Life Sciences Inc (NASDAQ:KZR) has received a consensus recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $26.50.
Several equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of Kezar Life Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Saturday, March 16th. William Blair restated an “outperform” rating on shares of Kezar Life Sciences in a research report on Tuesday, March 12th.
Several hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in shares of Kezar Life Sciences by 2,314.5% in the 3rd quarter. BlackRock Inc. now owns 241,446 shares of the company’s stock worth $5,169,000 after buying an additional 231,446 shares in the last quarter. New York State Common Retirement Fund purchased a new stake in shares of Kezar Life Sciences in the 4th quarter worth about $73,000. Bank of New York Mellon Corp purchased a new stake in shares of Kezar Life Sciences in the 4th quarter worth about $411,000. Northern Trust Corp boosted its position in shares of Kezar Life Sciences by 8.7% in the 4th quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock worth $1,345,000 after buying an additional 4,581 shares in the last quarter. Finally, BB Biotech AG purchased a new stake in shares of Kezar Life Sciences in the 4th quarter worth about $19,315,000. Institutional investors own 51.88% of the company’s stock.
Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. As a group, equities research analysts expect that Kezar Life Sciences will post -2.04 EPS for the current year.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Featured Article: Cash Asset Ratio
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.